Advances in Personalized Treatment of Cancer (Powered By: 4oncommunity)

Guest Editors:

Prof. Dr. Matteo Fassan

Dr. Umberto Malapelle

Dr. Nicola Fusco

Prof. Dr. Fabio Pagni

Dr. Carmen Criscitiello

Dr. Sara Pilotto

Deadline for manuscript submissions:
closed (20 July 2023)

Message from the Guest Editors

We are experiencing an amazing era of advances in the diagnosis and treatment of cancer. In this evolving scenario, predictive molecular pathology is called to face new challenges. Our increased diagnostic resolution, coupled with the integration of clinicopathologic information, and big molecular data, is allowing for a growth in the selective capacity of molecular targeted treatments. Novel biomarkers at genomic, transcriptomic, proteomic, and immunologic levels have been discovered, and more accurate testing methods and guidelines are expected. These biomarkers are strongly impacting treatment decision making in patients with cancer.

This Special Issue is edited by the Scientific Board of 4oncommunity (www.4oncommunity.com Twitter: @4oncommunity) to provide a comprehensive portrait of the current state of knowledge of biomarkers for the clinical management of cancer patients. One of the aims of this initiative is to foster a novel approach in collaborating between scientists working on cancer. We especially welcome review articles (either systematic or discursive), original translational research studies, and short communications.

mdpi.com/si/97984

Special Issue

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory
Medicine and Pathobiology,
Department of Surgery,
University of Toronto, 6 Queens
Pk Crescent W,F, Toronto, ON
M5S 3H2, Canada

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, PubMed, PMC, Embase, and other databases.
Journal Rank: CiteScore - Q1 (Medicine (miscellaneous))

Contact Us